The use of extracorporeal membrane oxygenation in clinical practice

Hasan, Khubbaib; Parmar, Sheena; Harky, Amer

doi:10.1111/jocs.14703

J Card Surg

2020

DOI: 10.1111/jocs.14703

|View full text |Cite

The use of extracorporeal membrane oxygenation in clinical practice

Khubbaib Hasan

Sheena Parmar

Amer Harky

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The employment of extracorporeal membrane oxygenation (ECMO) as supportive therapy for COVID‐19‐related ARDS has also been advocated for by the WHO and Extracorporeal Life Support Organization (ELSO) 5 . This rescue therapy 6 is primarily recommended as a last resort, subsequent to unavailing results from conventional therapies 7 for COVID‐19 patients with a limited number of co‐morbidities who do not have severe multisystem organ failure 8 . Yet, according to the ELSO Registry, the in‐hospital mortality rate remains as high as 47% 9 .…”

mentioning

confidence: 99%

COVID‐19, ECMO, and respiratory infection: A new triad?

Zaidi

Nguyen

Harky

2022

Journal of Cardiac Surgery

Self Cite

View full text Add to dashboard Cite

In December 2019, the initial outbreak of COVID-19 started in Wuhan, China, which rapidly escalated to an international scale within weeks. 1 This ultimately resulted in it being declared as a global pandemic by the World Health Organization (WHO) in March 2020. 2 This highly contagious respiratory infection has since mutated and evolved to enable viral survival in the host. 3 Treatment pathways for the virus have also changed and improved, accompanied by more knowledge of the disease pathogenesis. For example, May 2020 saw the introduction of the broad-spectrum antiviral medication Remdesivir, followed by the FDA's approval of monoclonal antibodies such as Bamlanivimab in November 2020. 4 The employment of extracorporeal membrane oxygenation (ECMO) as supportive therapy for COVID-19-related ARDS has also been advocated for by the WHO and Extracorporeal Life Support Organization (ELSO). 5 This rescue therapy 6 is primarily recommended as a last resort, subsequent to unavailing results from conventional therapies 7 for COVID-19 patients with a limited number of co-morbidities who do not have severe multisystem organ failure. 8 Yet, according to the ELSO Registry, the in-hospital mortality rate remains as high as 47%. 9 This sparks some questions on the use of this therapy in COVID-19 patients with ARDS. Whilst there are some studies to suggest the clinical benefit of ECMO, 10 there is also concern over potential increased mortality and morbidity of up to 65% in some cases. 11

show abstract

mentioning

confidence: 99%

COVID‐19, ECMO, and respiratory infection: A new triad?

Zaidi

Nguyen

Harky

2022

Journal of Cardiac Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The use of extracorporeal membrane oxygenation in clinical practice

Cited by 1 publication

References 3 publications

COVID‐19, ECMO, and respiratory infection: A new triad?

COVID‐19, ECMO, and respiratory infection: A new triad?

Contact Info

Product

Resources

About